Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Nov;58(11):6993-5.
doi: 10.1128/AAC.04035-14. Epub 2014 Sep 8.

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity

Dong Sik Jung  1 , Frank P Tverdek  2 , Dimitrios P Kontoyiannis  3
Affiliations
Comparative Study

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity

Dong Sik Jung et al. Antimicrob Agents Chemother. 2014 Nov.

Abstract

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Distribution of serum POSA levels in 12 leukemia patients showing higher levels when these patients received POSA tablets (right) than when the patients received suspension (left). The dotted line depicts the target level for prophylaxis (>700 ng/ml). (B) Comparative measurements in 9 leukemia patients. Three patients were excluded either because the serum levels were measured too early or because of missing data. The black line in the box and corresponding concentrations represent the median serum POSA levels. The black line between dots depicts an increased change of median concentration for each patient who switched from suspension to tablets.
See this image and copyright information in PMC

References

    1. Leventakos K, Lewis RE, Kontoyiannis DP. 2010. Fungal infections in leukemia patients: how do we prevent and treat them? Clin. Infect. Dis. 50:405–415. 10.1086/649879. - DOI - PubMed
    1. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik J-AH, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2–12. 10.1086/508774. - DOI - PubMed
    1. Krishna G, Ma L, Martinho M, O'Mara E. 2012. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196–4201. 10.1128/AAC.00222-12. - DOI - PMC - PubMed
    1. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. 2012. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67:2725–2730. 10.1093/jac/dks268. - DOI - PMC - PubMed
    1. Kraft WK, Chang P, van Iersel ML, Waskin H, Krishna G, Kersemaekers W. 2014. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob. Agents Chemother. 58:4020–4025. 10.1128/AAC.02448-13. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources